FERRER
The international pharmaceutical BCorp company Ferrer continues to strengthen its focus on pulmonary vascular and interstitial lung diseases by announcing the expansion of its current distribution agreement with United Therapeutics Corporation (Nasdaq: UTHR) for Tyvaso® (treprostinil inhalation solution*) – a pharmaceutical drug-device combination product authorized for the treatment of WHO Group 3 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD), and for WHO Group 1 Pulmonary Arterial Hypertension (PAH).
Both companies have signed the distribution rights for two new potential indications of the molecule, Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF), two rare diseases characterized by scarring of lungs which results in difficulty for patients to breathe, leading to poor quality of life and even death. Current available treatments for IPF and PPF have only been shown to slow disease progression, whereas treprostinil inhalation solution could potentially offer a new treatment option in these patients.
“The pulmonary vascular and interstitial lung diseases field is very important for us”, said Oscar Pérez, Chief Scientific and Business Development Officer at Ferrer. “Strengthening our partnership with United Therapeutics Corporation can advance our purpose of using business to fight for social justice through the delivery of new solutions for people, families and caregivers living with devastating diseases”.
Under the expanded agreement, Ferrer has been appointed as the exclusive, worldwide distributor (except for the US, Canada, Japan, China, and Israel), to make this therapeutic option available upon approval for the treatment of IPF and PPF and keep delivering transformative solutions to the patients in need.
The announcement leverages Ferrer’s strong capabilities and expertise in pulmonary vascular and interstitial lung diseases and underscores both companies’ commitment to expanding global access to treprostinil inhalation solution for IPF and PPF patients, if approved.
Treprostinil inhalation solution is currently being assessed in three Phase 3 clinical trials: two in IPF patients (with over 1.000 subjects combined), and one in PPF patients (with 698 subjects), with a 52-week follow-up and collectively covering a global study geography.
* Treprostinil inhalation solution is a prostacyclin mimetic indicated for the treatment of Pulmonary arterial hypertension (PAH; WHO Group 1) and Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3). Tyvaso® for PH-ILD is currently authorized in the US, Israel, Chile, Dominican Republic, and Argentina, and under regulatory review in Japan, and for WHO Group 1 Pulmonary Arterial Hypertension (PAH), currently authorized in the US, Israel, Argentina, Colombia, Japan, and Dominican Republic. Regarding the registration of Tyvaso® (treprostinil) inhalation solution for the treatment of PH-ILD, Ferrer has just obtained the marketing authorization in Chile and Dominican Republic and will focus on obtaining it in the United Kingdom as well. Further assessment of Tyvaso® PH-ILD for the European Union will continue.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528462230/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting indgår samarbejde med virksomheden Vivaldi31.10.2025 15:43:00 CET | Pressemeddelelse
Andersen Consulting annoncerer en samarbejdsaftale med Vivaldi, der er et globalt konsulentfirma inden for forretnings- og brandstrategi, hvilket styrker organisationens løsninger inden for strategi og forretningstransformation. Vivaldi, der blev oprettet i 1999, er kendt for sin tilgang, som forener brand, forretning og teknologi for at hjælpe kunder med at bevare deres position som markedsledere. Med aktiviteter i USA, Europa og Latinamerika samarbejder Vivaldi med nogle af verdens førende virksomheder om at styrke markedspositioner, accelerere innovation og udvikle kundecentrerede forretningsmodeller. I en tid, der er præget af hurtig forandring, drevet af kunstig intelligens, platformdynamikker og kontinuerlig fornyelse, hjælper Vivaldi sine kunder med at gentænke, hvordan forretningsværdi skabes og udnyttes. Virksomhedens tværfaglige teams kombinerer dyb indsigt i forbrugeradfærd og markedsudvikling med strategisk, kreativ og finansiel ekspertise for at levere skræddersyede løsnin
Andersen Consulting styrker sin platform gennem samarbejde med threon31.10.2025 15:35:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for forretningstransformation og digital transformation via en samarbejdsaftale med threon, der er et belgisk konsulentfirma, som er kendt for at levere pragmatisk og helhedsorienteret støtte til strategiimplementering. I mere end 20 år har threon været en vigtig rådgiver for organisationer, der ønsker at omsætte store idéer til reel forretningsmæssig effekt. Virksomheden er specialiseret i strategisk porteføljestyring, digital transformation og ledelsestræning for at hjælpe ledere med at omsætte visioner til konkret handling. threons unikke tilgang kombinerer projektlevering, udvikling af medarbejdere og intelligente softwareløsninger, hvilket giver teams mulighed for at levere hurtigere, opskalere i det rette tempo og opnå varige resultater. Tom Dedecker, CEO for threon, udtalte: "Vi skaber fokus og ro i organisationer, hvilket gør det muligt at træffe hurtigere beslutninger og gennemføre en bæredygtig transformation, der er forankre
SBC Medical to Announce Q3 2025 Financial Results on November 14 and Hold Earnings Call on November 1731.10.2025 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it will release its Q3 2025 financial results on Friday, November 14, 2025, before the U.S. market opens. The Company will hold a Earnings Call on Monday, November 17, 2025 at 5:00 p.m. Eastern Time to discuss the financial results and take questions live. Please register in advance for the conference using the link provided below. https://edge.media-server.com/mmc/p/e2znwqtx It will automatically direct you to the registration page for “SBC Q3 2025 Financial Results Presentation.” Please follow the steps to enter your registration details and click “Submit.” Upon registration, you will be able to access the dedicated conference call viewing site. In addition to viewing the conference call, this site provides access to information about the speakers as well as pas
Motive Brings Seamless eSIM Activation to Luxury European Automotive Brand in Latin America31.10.2025 11:00:00 CET | Press release
Motive, a global leader in connected device lifecycle management and automation, has announced a landmark partnership with a leading operator in Central and South America, bringing seamless and secure mobile connectivity to a luxury European automotive brand’s vehicles in Mexico. The solution—powered by Motive's Entitlement Server—enables the carrier’s subscribers to link their mobile identities directly to their vehicles using embedded SIM (eSIM) technology leveraging GSMA’s mobile connectivity standards. This automotive-first for the Latin America region allows drivers to activate their mobile subscription upon entering a vehicle, delivering a personalized, connected experience on par with their smartphones. Whether for entertainment, navigation, or communication services, users benefit from uninterrupted access to their mobile services with enhanced security and privacy. "This deployment showcases the power of intelligent entitlement and provisioning," said Francisco Viana, VP Sales
Hanshow and Unide Partner to Advance Store Modernization under the “Plan Unide 2.0” Strategy31.10.2025 02:45:00 CET | Press release
Hanshow, a global leader in digital retail solutions, has announced a strategic collaboration with Unide Corporativa, one of Spain’s most established food retail cooperatives, to advance store digitalization and operational efficiency under its new strategic roadmap “Plan Unide 2.0” (2025–2028). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030921658/en/ Founded over 90 years ago, Unide unites hundreds of independent grocery retailers across Spain under a cooperative model built on proximity, freshness, and community service. With Plan Unide 2.0, the cooperative aims to strengthen competitiveness through member business development, store modernization, and new store openings—a roadmap to ensure sustainable growth in an evolving retail landscape. Unide faces operational challenges common to cooperative retail: manual paper label updates, inconsistent pricing, and limited promotional agility across its network. Meanwhile,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom